期刊文献+

Delivery of therapeutic oligonucleotides in nanoscale 被引量:1

原文传递
导出
摘要 Therapeutic oligonucleotides(TOs)represent one of the most promising drug candidates in the targeted cancer treatment due to their high specificity and capability of modulating cellular pathways that are not readily druggable.However,efficiently delivering of TOs to cancer cellular targets is still the biggest challenge in promoting their clinical translations.Emerging as a significant drug delivery vector,nanoparticles(NPs)can not only protect TOs from nuclease degradation and enhance their tumor accumulation,but also can improve the cell uptake efficiency of TOs as well as the following endosomal escape to increase the therapeutic index.Furthermore,targeted and on-demand drug release of TOs can also be approached to minimize the risk of toxicity towards normal tissues using stimuli-responsive NPs.In the past decades,remarkable progresses have been made on the TOs delivery based on various NPs with specific purposes.In this review,we will first give a brief introduction on the basis of TOs as well as the action mechanisms of several typical TOs,and then describe the obstacles that prevent the clinical translation of TOs,followed by a comprehensive overview of the recent progresses on TOs delivery based on several various types of nanocarriers containing lipid-based nanoparticles,polymeric nanoparticles,gold nanoparticles,porous nanoparticles,DNA/RNA nanoassembly,extracellular vesicles,and imaging-guided drug delivery nanoparticles.
出处 《Bioactive Materials》 SCIE 2022年第1期292-323,共32页 生物活性材料(英文)
基金 This work was financially supported by the Natural Science Foundation of China(81871472) Natural Science Foundation of Guangdong Province(Project No.2019A1515010696 and 2021A1515012333) Shenzhen Municipal Science,Technology and Innovation Commission(Project No.JCYJ20190807163003704) “100 Talents Program”of the start-up foundation from Sun Yat-sen University,Academy of Finland(328933)and Sigrid Jus´elius Foundation.
  • 相关文献

参考文献2

二级参考文献55

  • 1曾维忠,邓凌燕,周锐.靶向MMP-9脱氧核酶抑制人肺腺癌细胞的粘附与迁移的实验研究[J].中国肺癌杂志,2008,11(6):765-768. 被引量:3
  • 2Patil, S. D.; Rhodes, D. G.; Burgess, D. J. DNA-based therapeutics and DNA delivery systems: A comprehensive review. AAPSL 2005, 7, E61-E77. 被引量:1
  • 3Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193-204. 被引量:1
  • 4Blechinger, J.; Bauer, A. T.; Torrano, A. A.; Gorzelanny, C., Br/iuchle, C.; Schneider, S. W. Uptake kinetics and nano- toxicity of silica nanoparticles are cell type dependent. Small 2013, 9, 3970-3980. 被引量:1
  • 5Pendergrast, P. S.; Marsh, H. N.; Grate, D.; Healy, J. M.; Stanton, M. Nucleic acid aptamers for target validation and therapeutic applications. J. Biomol. Tech. 20115, 16, 224-234. 被引量:1
  • 6Niidome, T., Huang, L. Gene therapy progress and prospects: Nonviral vectors. Gene Ther. 2002, 9, 1647-1652. 被引量:1
  • 7Herweijer, H.; Wolff, J. A. Progress and prospects: Naked DNA gene transfer and therapy. Gene Ther. 2003, 10, 453-458. 被引量:1
  • 8E1-Aneed, A. An overview of current delivery systems in cancer gene therapy. J. Control Release 2004, 94, 1-14. 被引量:1
  • 9Wong, S. Y.; Pelet, J. M.; Putnam, D. Polymer systems for gene delivery--Past, present, and future. Prog. Polym. Sci. 2007, 32, 799-837. 被引量:1
  • 10Thomas, C. E.; Ehrhardt, A.; Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4, 346-358. 被引量:1

共引文献29

同被引文献17

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部